VesPro GHS Max - 80 Caps - Advanced gh releaser

VesPro GHS Max 80 Caps Advanced gh releaser

GHS MAX with advanced human growth hormone releasing formula gives double the amount of peptides in a micro encapsulation delivery system to better utilize the peptides and deliver them to your receptor sites. These improvements have shown in our studies to greatly increase the effectiveness and potency of our Growth Hormone secretagogue.

NGH protein/peptide complex:

Powdered glandular protein with APFTM , providing naturally occurring peptides, amino acids, L-Glutamine, L-Arginine, L-Glycine, L-Lysine, L-Ornithine, L-Valine, L-Leucine as well as Isoleucine, in a sequenced form that nutritionally supports the body in its natural function of growth hormone release.

GH Support Herbal base: A proprietary blend of Tribulus Extract, Shilajit Extract, Schizandra Extract, PABA, Licorice, Southern Bayberry and Kelp.

Nutraceutical Matrix: Colostrum, Mucuna Extract, MSM, GABA.

APFTM: Acid Protection FactorTM, natural proprietary Acid Protection process designed to Chaperon the transport of amino acids and peptides safely through the acid of the stomach for the normal sequencing, complexing and absorption in the intestinal tract and help provide bioavailability to their naturally intended target uptake sites.Other ingredients: Calcium Silicate, Cellulose, Vegetable Magnesium Stearate. This product contains no wheat, corn, soy, dairy, yeast, sugar, starch or artificial ingredients.

CFS Clinical Trial Results (click for more information)

Read Testimonials (click for more information)

Frequently Asked Questions (click for more information)

More about Growth Hormone (click for more information)

Supplement Facts: Now with twice the amount of NGH Protein / Pepetide Complex and one and a half times the amount of Neutraceutical Matrix*** Serving Size: 4 tablets
Amount Per Serving		% Daily Value *
NGH Protein / Peptide Complex	2985 mg	** %
GH Support Herbal Blend	720 mg	** %
Nutraceutic Matrix	825 mg	** %
Niacinamide	20 mg	125 %
Folic Acid	270 mcg	67.5 %
Zinc Gluconate	15mg	100 %

*Percentage Daily Values are based on a 2,000 calorie diet.
** Daily value not established.
*** when compared to VesPro GHS

Usage Directions: Take 4 tablets on an empty stomach (3 hours after eating) for 5 consecutive days. Then take 2 days off. Repeat this cycle for 90 days. Then take 2 weeks off before starting again. Wait an hour to eat after taking tablets.

Storage: Store in cool, dry area. Keep out of reach of children.

Warning: Not intended for use by pregnant or lactating women.

CAUTION: VesPro GHS Max is a nutritional supplement and is not intended to treat, cure or diagnose diseases. If you have serious health problems and are taking prescription medications, always consult your doctor before taking any form of nutritional supplements.
Disclaimer: Studies showing that injected HGH provides anti-aging benefits do not constitute competent and reliable scientific evidence that a pill or spray will provide the same benfit.

• Human

• Growth Hormone (HGH)
  
• 
  
• Growth Hormone and Aging
  
• 
  

• Growth hormone declines with age in every animal species

• that have been tested to date. In humans, the amount of
• growth hormone after the age of 21 to 31 falls about 14%
• per decade, so that the total 24-hour growth hormone production
• rate is reduced in half by the age of 60. In numerical values,
• we produce on a daily basis about 500 micrograms at 20 years
• of age , 200 micrograms at 40 years , and 25 micrograms
• at 80 years old.
  
• 
  

• The easiest way to measure growth hormone in the body is

• by measuring plasma IGF-1 levels. Under 350 IU is considered
• evidence of deficiency. Between the ages of 20 to 40 years,
• less than 5% of healthy men have less than 350 IU per liter
• of IGF-1 levels. But after 60, 30% of apparently healthy
• men have this low amount. And after age 65, about half the
• population is partially or wholly deficient in growth hormone.
  
• 
  

• Total daily hGH secretion declines in humans with increasing

• age. "Elederly" levels are reached by age 35-40.
  
• 
  

• 

A CLINICAL TRIAL OF VESPRO GROWTH HORMONE SECRETAGOGUE IN PERSONS WITH CHRONIC FATIGUE SYNDROME

Salvato, P., Thompson, C., Bayou City Medical Center Hospital, Houston, Texas, USA

Objective:

To determine if a growth hormone secretagogue called SomatoMed (VesPro GHS Growth Hormone) was safe and efficacious in patients with CDC defined Chronic Fatigue Syndrome (CFS).

Methods:

Body cell mass measured by BIA (BCM) natural killer number (NK#), and Insulin growth factor-1 (IgF-1) levels were evaluated in 20 CFS patients. These measures were assessed at study initiation and monthly for two months. Subjective measure of symptoms, cognitive function, activities, of daily living and sleep disturbance were also assessed monthly for two months.

RESULTS:

Objective

BCM: 55% patients had increase in BCM (muscle) of 1 lb. or more;
35% patients lost weight due to decrease in fat body mass;
10% patients gained muscle from 5 - 11 lbs;


IgF-1: 85% patients had increase in their IgF-1 level of 20% or more;

NK#: 80% patients had increase of their NK# of 30% or more;

Subjective

Sleep: 80% patients had marked improvement in their sleep;

Cognitive: 75% patients had marked improvement in cognitive function'

Muscle Pain: 60% patients had improvement in muscle pain;

Fatigue: 90% patients had improvement in fatigue;

Side Effects: 45% patients had transient muscle and joint pain during initiation of therapy; 40% patients had mild edema;

Conclusion:

An oral secretagogue, VesPro GHS, has been found to be safe and efficacious therapy; capable of improving many of the clinical signs and symptoms associated with the Chronic Fatigue Syndrome. Clinically, the efficacy of SomatoMed has been verified through IgF-1 measurements and patient assessment, as well as improvement in immune function and body cell mass. It is of interest to note that even in patients who did not raise IgF-1 levels, significant improvement in sleep and cognition were still noted. This product deserves further study in patients with Chronic Fatigue Syndrome.